Otsuka Pharmaceutical Company, Limited

I. Otsuka Pharmaceutical Co., Ltd.

Keigo Yamada

Yusuke Kato

Takakuni Matsuda

Yasuhiro Menjo

Yuso Tomohira

Kazumi Kondo

Shin Miyamura

Takahiro Tomoyasu

Makoto Komatsu

Fumitaka Goto

Tadashi Mukai

Makoto Inada

Nobuhiro Ikei

Masateru Miyake

Hideji Nonomura

Atsunari Noda

Shinsuke Nakagawa

Yoshikazu Oka

Masafumi Toda

The present invention provides a benzoazepine compound represented by following general formula (1): or a salt thereof,wherein R represents a hydrogen atom, a hydroxy group optionally protected with a protecting group, etc., Rrepresents a hydrogen atom or hydroxy-protecting group, and X represents an oxygen atom or a sulfur atom. The benzoazepine compound of the present invention and salts thereof have high solubility in water, and can be suitably used for injections.

Water-soluble benzoazepine compound and its pharmaceutical composition

The present invention provides a benzoazepine compound represented by following general formula (1): or a salt thereof,

The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein Rrepresents a &#x2014;CO&#x2014;(CH)&#x2014;CORgroup (wherein n is an integer of 1 to 4, and Ris (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5 -methyl-2-oxo-1,3-dioxol-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.

Benzazepine derivatives useful as vasopressin antagonists

The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein Rrepresents a &#x2014;CO&#x2014;(CH)&#x2014;CORgroup (wherein n is an integer of 1 to 4, and Ris (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxol-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.

The present invention provides a benzazepine compound that can maintain for a long period of time the blood level of tolvaptan enabling to provide the desired pharmaceutical effects. The benzazepine compound of the present invention is represented by general formula (1) wherein Rrepresents a &#x2014;CO&#x2014;(CH)&#x2014;CORgroup (wherein n is an integer of 1 to 4, and Ris (2-1) a hydroxy group; (2-2) a lower alkoxy group optionally substituted with a hydroxy group, a lower alkanoyl group, a lower alkanoyloxy group, a lower alkoxycarbonyloxy group, a cycloalkyloxycarbonyloxy group, or 5-methyl-2-oxo-1,3-dioxo-4-yl; or (2-3) an amino group optionally substituted with a hydroxy-lower alkyl group), or the like.

Provided is a cilostazol preparation which comprises incorporating a fine powder of cilostazol into a dispersing and/or solubilizing agent thereby to enhance the dispersibility and/or solubility. Further, provided is a process for improving absorbability of a slightly soluble drug such as cilostazol even at the lower portion of the digestive tract, wherein said drug is hard to be absorbed at the lower portion of the digestive tract when a conventional method is used. According to the present invention, cilostazol is absorbed enough even at the lower portion of the digestive tract to have an effect as thrombolytic drug, cerebral circulation improving drug or the like.

Cilostazol preparation

Preparations whereby reduction or acceleration of the gastric emptying rate can be noninvasively evaluated: and a method of evaluating the gastric emptying rate by using these preparations. Thus, reduction or acceleration of the gastric emptying rate can be safely and conveniently examined. Namely, theses preparations are useful in objectively diagnosing the gastric motor function, as well as in evaluating and judging the drug effect or therapeutic effect of a drug concerning the gastric motor function on individual patients.

Growing community of inventors

Tokushima, Japan

Keigo Yamada